BioCentury
ARTICLE | Finance

Ebb & Flow

August 21, 2006 7:00 AM UTC

Until last week,Third Point had been waging a quiet war against the board of Nabi (NABI), demanding in two SEC filings in April and June that the company seek a buyer. Last week, the hedge fund ratcheted up a notch, with both another SEC filing and a press release highlighting its grievances with the biotech's board and CEO Thomas McLain.

In short, Third Point wants the board to authorize Bank of America to find a buyer for the company. ...